tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Kazia Therapeutics (KZIA), EyePoint Pharmaceuticals (EYPT) and Oramed Pharmaceuticals (ORMP)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Kazia Therapeutics (KZIAResearch Report), EyePoint Pharmaceuticals (EYPTResearch Report) and Oramed Pharmaceuticals (ORMPResearch Report).

Kazia Therapeutics (KZIA)

H.C. Wainwright analyst Sean Lee CFA downgraded Kazia Therapeutics to Hold today. The company’s shares closed last Monday at $1.92, close to its 52-week low of $1.63.

According to TipRanks.com, CFA has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -16.3% and a 24.1% success rate. CFA covers the Healthcare sector, focusing on stocks such as Monopar Therapeutics Inc, CASI Pharmaceuticals, and Virios Therapeutics.

The the analyst consensus on Kazia Therapeutics is currently a Hold rating.

See today’s best-performing stocks on TipRanks >>

EyePoint Pharmaceuticals (EYPT)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on EyePoint Pharmaceuticals, with a price target of $24.00. The company’s shares closed last Monday at $9.11, close to its 52-week low of $7.00.

According to TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -13.6% and a 32.0% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and Stealth Biotherapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for EyePoint Pharmaceuticals with a $22.50 average price target, implying a 150.0% upside from current levels. In a report issued on July 19, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $31.00 price target.

Oramed Pharmaceuticals (ORMP)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Oramed Pharmaceuticals, with a price target of $32.00. The company’s shares closed last Monday at $8.36.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -41.3% and a 14.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, MoonLake Immunotherapeutics, and Oncternal Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Oramed Pharmaceuticals with a $31.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on KZIA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More